Comparative Pharmacology
Head-to-head clinical analysis: ISMO versus MINITRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMO versus MINITRAN.
ISMO vs MINITRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing cGMP levels, leading to smooth muscle relaxation and vasodilation.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing cGMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
None Documented
None Documented
Clinical Note
moderateVismodegib + Digoxin
"Vismodegib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateVismodegib + Digitoxin
"Vismodegib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateVismodegib + Deslanoside
"Vismodegib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateVismodegib + Acetyldigitoxin
"Vismodegib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator